Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541540 | 0.82 | KMT2A (0.61) | ALDH1A1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL10636222 | 0.80 | KMT2A (0.35) | ALDH1A1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL4980430 | 0.80 | PTK2 (0.37) | ALDH1A1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL17837166 | 0.76 | POLB (0.49) | ALDH1A1KMT2AMEN1MAPTHSD17B10 | |
| SCHEMBL14744096 | 0.76 | MAPT (0.35) | ALDH1A1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL164691 | 0.74 | — | — | |
| SCHEMBL8551215 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL5067843 | 0.70 | — | — | |
| SCHEMBL9528369 | 0.70 | — | — | |
| SCHEMBL161830 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311813-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-08-07 | — | — | EP | disclosed |
| US-10053467-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-21 | — | — | US | disclosed |
| EP-3311813-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Dart Neuroscience (Cayman) Ltd (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-2182809-B1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2017-07-20 | — | — | US | disclosed |
| US-9650349-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-05-16 | — | — | US | disclosed |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE LLC | 2015-11-26 | — | — | US | disclosed |
| US-9029397-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-05-12 | — | — | US | disclosed |
| US-8921399-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2014-12-30 | — | — | US | disclosed |
| US-20130053361-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2013-02-28 | — | — | US | disclosed |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2012-08-09 | — | — | US | disclosed |
| US-8222243-B2 | Therapeutic isoxazole compounds | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2012-07-17 | — | — | US | disclosed |
| EP-2182809-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009029632-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053361-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885KMT2A 1192/4885MEN1 3625/4885 |
| US-10053467-B2 | Therapeutic isoxazole compounds | MAOB, MAOA, XDH | ALDH1A1 254/4885KMT2A 1192/4885MEN1 3625/4885 |
| US-20150336941-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885KMT2A 1192/4885MEN1 3625/4885 |
| US-20170204111-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885KMT2A 1192/4885MEN1 3625/4885 |
| US-20120202786-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885KMT2A 1192/4885MEN1 3625/4885 |
| US-20090062252-A1 | THERAPEUTIC ISOXAZOLE COMPOUNDS | MAOB, MAOA, XDH | ALDH1A1 254/4885KMT2A 1192/4885MEN1 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.